Neuroendocrine Tumours

This is a promotional website intended for UK healthcare professionals. If you are a member of the public, please click here.

Welcome to the Radioligand Therapy Hub.

Please confirm whether you are a UK healthcare professional or a member of the public. This website is not suitable for healthcare professionals outside of the United Kingdom.

I am a UK Healthcare Professional

No, I am a member of the public

Search Results

RLT Home
Neuroendocrine tumours
LUTATHERA® (lutetium [177Lu] oxodotreotide)
PRRT Practical Resources
Contact Us
Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan)

Popular Search

prrt
masterclass
part
2022
2023

Ask Speakers

Medical Information Request

Welcome to the Radioligand Therapy Hub.

Please confirm whether you are a UK healthcare professional or a member of public.

Yes, I am a UK healthcare professional

No, I am a member of the public

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]

Cookie Settings

Site directory

This site is intended for a UK healthcare professional audience and NHS relevant decision makers only.

Novartis Pharmaceuticals UK Limited is a limited liability company registered in England and Wales under number 119006.
Registered office: The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ

UK | April 2024 | AAA-Lu177-UK-2429